Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Conferences |3 August 2010

Systematic Review: Factors Associated With Risk for and Possible Prevention of Cognitive Decline in Later Life Free

Brenda L. Plassman, PhD; John W. Williams Jr., MD, MHSc; James R. Burke, MD, PhD; Tracey Holsinger, MD; Sophiya Benjamin, MD

Brenda L. Plassman, PhD

John W. Williams Jr., MD, MHSc

James R. Burke, MD, PhD

Tracey Holsinger, MD

Sophiya Benjamin, MD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
Acknowledgment: The authors thank Connie Schardt for providing literature search and retrieval support; Vic Hasselblad, PhD, for statistical support; Remy Coeytaux, MD, PhD, Jennifer McDuffie, PhD, Ravi Dhurjati, DPhil, Carolina Aponte Urdaneta, MD, and Katie Dore, PA-C, for assisting in the preparation of evidence tables; Julian Irvine, MCM, for project management; Rebecca Gray, DPhil, for editorial assistance; and Alice Thacher and Vincent Miller for research assistance.
Grant Support: By the Agency for Healthcare Research and Quality (contract HHSA 290-2007-10066-I) and the National Institute on Aging, through the Office of Medical Applications of Research, National Institutes of Health.
Potential Conflicts of Interest: Drs. Plassman, Williams, Burke, Holsinger, and Benjamin have disclosed the following: Grants received (money to institution): Agency for Healthcare Research and Quality. Drs. Plassman, Williams, Burke, and Holsinger have also disclosed the following: Grants received/pending: U.S. Department of Veterans Affairs. Support for travel to meetings for the study or otherwise (to institution): Agency for Healthcare Research and Quality. Dr. Burke has further disclosed the following: Grants received/pending: National Institutes of Health, Toyama, Lilly, Novartis. Consultancy: Bristol-Myers Squibb. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-1107.
Requests for Single Reprints: Brenda L. Plassman, PhD, Duke University Medical Center, 905 West Main Street, Suite 25-D, Box 41, Durham, NC 27701; e-mail, brenda.plassman@duke.edu.
Current Author Addresses: Dr. Plassman: Duke University Medical Center, 905 West Main Street, Suite 25-D, Box 41, Durham, NC 27701.
Dr. Williams: 2424 Erwin Road, Suite 1105, Hock Plaza, Durham, NC 27705.
Dr. Burke: Duke University Medical Center, Box 2900, Durham, NC 27710.
Dr. Holsinger: Durham Veterans Administration Medical Center, Mail Station 116A, 508 Fulton Street, Durham, NC 27707.
Dr. Benjamin: Duke University Medical Center, Box 3925, Durham, NC 27710.
Author Contributions: Conception and design: B.L. Plassman, J.W. Williams, J.R. Burke.
Analysis and interpretation of the data: B.L. Plassman, J.W. Williams, J.R. Burke, T. Holsinger, S. Benjamin.
Drafting of the article: B.L. Plassman, J.W. Williams, J.R. Burke.
Critical revision of the article for important intellectual content: B.L. Plassman, J.W. Williams, J.R. Burke, T. Holsinger, S. Benjamin.
Final approval of the article: B.L. Plassman, J.W. Williams, J.R. Burke, T. Holsinger, S. Benjamin.
Statistical expertise: J.W. Williams.
Obtaining of funding: J.W. Williams.
Collection and assembly of data: B.L. Plassman, J.W. Williams, J.R. Burke, T. Holsinger, S. Benjamin.
  • From Duke University Medical Center, Durham Veterans Administration Medical Center, and Duke Evidence-based Practice Center, Durham, North Carolina.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • Methods
    • Results
    • Discussion
      1. References
    • Appendix
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
Persons with cognitive decline are at increased risk for progressing to mild cognitive impairment (MCI) and dementia. Such intellectual deterioration is feared and often broadly affects quality of life because of limitations on functioning in daily life and increased disability. The term cognitive decline actually reflects a continuum of cognitive changes; some are considered to be within the spectrum of normal aging, whereas others exceed expected decline and are categorized as mild impairment. Typically, performance in 1 or more cognitive domains, such as memory, orientation, language, executive function, and praxis, is assessed to determine decline, but the diagnostic threshold between normal and pathologic cognitive changes is imprecise. Pathologic cognitive decline is often referred to as MCI or cognitive impairment without dementia. The diagnostic criteria for MCI and cognitive impairment without dementia are still evolving, but guidelines generally include greater-than-expected cognitive decline for the person's age and education level and no more than mild functional impairment that is insufficient to meet the threshold for a diagnosis of dementia. Each term has multiple subtypes, which reflect multiple causes and outcomes.
Findings from numerous epidemiologic and clinical studies suggest that multiple biological, behavioral, social, and environmental factors may contribute to the risk for cognitive decline. However, few systematic reviews have examined the breadth of evidence on the wide range of factors that are potentially associated with cognitive decline or the evidence about interventions that may slow decline. Our review addresses this gap in the literature to determine whether evidence is sufficient to warrant specific recommendations for behavioral, lifestyle, or pharmaceutical interventions targeted at maintaining cognitive ability in later life. We present evidence on the association between putative risk and protective factors for cognitive decline and the therapeutic or adverse effects of interventions for preserving cognition.

Methods

We developed and followed a standard protocol for all steps of this review. A technical report that details our methods, including the literature search strategies, and presents results for all 6 of the original key research questions is available at www.ahrq.gov. The 9, provides further details of our methods.

Key Questions

This evidence review addresses 2 of the 6 original key research questions developed by a National Institutes of Health (NIH) Office of Medical Applications of Research (OMAR) State-of-the-Science Conference planning committee. We refined the specific factors and interventions to be reviewed with input from members of the project's technical expert panel, representatives of NIH OMAR, and staff at the Agency for Healthcare Research and Quality (AHRQ).
First question (original key question 2): What factors are associated with the reduction of risk of cognitive decline in older adults?
Second question (original key question 4): What are the therapeutic and adverse effects of interventions to improve or maintain cognitive ability or function? Are there different outcomes in identifiable subgroups?

Data Sources and Selection

We searched for English-language publications in MEDLINE and the Cochrane Database of Systematic Reviews from 1984 through 27 October 2009. For topics with a recent, good-quality systematic review, we updated the review with primary literature published from 1 year before the search end date through 27 October 2009. We supplemented electronic searching by examining the bibliographies of reviews and primary studies. We developed a separate search strategy for the genetics literature by examining the HuGEpedia (1) and AlzGene (2) databases to identify relevant systematic reviews for genes identified as being of special interest, in consultation with the technical expert panel. We included studies of adults 50 years or older who were drawn from general populations in economically developed countries. We required a sample size of at least 300 for cohort studies and 50 for randomized, controlled trials (RCTs). We also required at least 1 year between exposure and final outcomes assessment. For the question on the factors associated with reducing the risk for cognitive decline, we restricted the study design to prospective cohort studies, except for traumatic brain injury, toxic environmental exposures, and sleep apnea, for which we also searched case–control designs because of the absence or limited number of cohort studies. For the question on the therapeutic effects of interventions to improve or maintain cognition, we restricted the study design to RCTs.
Two reviewers independently screened the title and abstract of each citation by using standardized guidelines based on the prespecified inclusion and exclusion criteria. Articles that either reviewer deemed potentially eligible underwent full-text screening. At the full-text screening stage, 2 independent reviewers read each article to determine whether it met eligibility criteria. We resolved disagreements by consensus.

Data Extraction and Quality Assessment

We extracted information on applicability, quality elements, intervention and exposure details, and outcomes. At least 1 reviewer confirmed all data extraction. We developed separate criteria for assessing the methodological quality of included systematic reviews, RCTs, and observational studies (9). In brief, we used the guidelines described in the User's Guides to the Medical Literature on systematic reviews (3) for systematic reviews. The 9 provides additional details. For RCTs, we used the key criteria described in the AHRQ methods manual for comparative effectiveness reviews (4), adapted to this specific topic. To assess individual observational studies, we adapted a basic set of quality criteria used in previous AHRQ evidence reports (5, 6). These criteria concern the methods used to select the cohort, the adequacy of the sample size, the methods used to ascertain exposure status and outcomes, the adequacy and completeness of follow-up, and the appropriateness of the analytic methods used (9).
We used principles from the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) working group to summarize the quality of the evidence overall for each factor as low, moderate, or high, reflecting the confidence that the estimate of effect is correct. The GRADE approach considers the body of evidence for each outcome and assigns initial ratings of low to observational studies and high to RCTs. These ratings may be modified by detailed study design, consistency, strength of association, dose–response effect, directness, precision, and whether all plausible confounding would reduce a demonstrated effect. One investigator, who is also a member of the GRADE working group, initially assigned the ratings. Another investigator reviewed them, and we discussed disagreements until consensus was reached.

Data Synthesis and Analysis

Synthesizing studies for these key questions was particularly challenging, because cognitive decline can be classified categorically by meeting specific criteria, such as those for MCI, or by exceeding a threshold for decline on 1 or more cognitive measures, typically a global measure, such as the Mini-Mental State Examination (MMSE). Cognitive decline may also be examined by using continuous measures of global cognition, domain-specific measures (such as memory or processing speed), or composites of multiple measures. Because of the heterogeneity of the continuous measures reported and the large scope of the review, we evaluated the relevance of studies that reported continuous measures for each exposure. When more than one half of the studies used categorical outcomes to address the question and the conclusions from the studies that used categorical and continuous outcomes were generally consistent, we did not provide detailed summaries of the studies that reported continuous outcomes. We did not quantitatively summarize the data because of the marked heterogeneity of the categorical outcomes.

Role of the Funding Source

An NIH OMAR State-of-the Science Conference planning committee developed the key questions. We refined our list of specific factors and interventions to review with input from members of the project's technical expert panel, representatives of NIH OMAR, and staff at the AHRQ. The AHRQ provided copyright release for this manuscript. Both AHRQ and NIH OMAR representatives were informed of key methodological decisions but did not participate in the literature search, data analysis, or interpretation.

Results

We screened 6907 titles and abstracts and evaluated 1626 full-text articles for our overall review. Of these, 250 primary publications met our eligibility criteria, of which 127 studies addressed the key question specific to factors associated with reducing the risk for cognitive decline and 22 focused on the therapeutic and adverse effects of interventions to improve or maintain cognitive ability or function (Figure). In addition, 25 systematic reviews met the eligibility criteria for the larger report (7); of these, 16 were included for the questions addressed here. We grouped the factors identified by the OMAR planning committee into 5 major categories: nutritional; medical (including medical conditions and prescription and nonprescription medications); social, economic, or behavioral; toxic environmental exposures; and genetic. Table 1 (8–114) summarizes the details of the evidence of the association between cognitive decline and each factor that had only observational data. Table 2 (115–174) provides the same details for factors that had both observational and RCT data.
Figure.
Literature search and selection.

RCTs = randomized, controlled trials.

Table 1.

Evidence of Association With Cognitive Decline for Factors With Observational Data Only

Table 1.

Table 2.

Evidence of Association With Cognitive Decline for Factors With Both Observational and RCT Data

Table 2.
The studies that we reviewed defined cognitive decline in different ways. About 10% defined cognitive decline as incident MCI or cognitive impairment without dementia. An estimated 40% of the studies defined it on the basis of change in performance on a single cognitive measure, typically a brief general cognitive function measure. About one half of these studies defined cognitive change as a continuous outcome, whereas the other half defined it as a categorical variable. Another 40% of the included studies assessed cognitive decline on the basis of multiple neuropsychological measures. Most of these studies reported decline as a continuous outcome. Some of these studies reported results for both the individual cognitive measures and a global composite measure that combined some or all of the tests. The specific cognitive tests varied across studies but typically included tests in several of the following domains: global cognitive function, verbal memory, visual memory, verbal fluency, naming, speed of processing, attention, executive function, working memory, and reasoning. Finally, about 10% of the studies defined decline on the basis of a composite global index of performance on all tests combined.
Our systematic review of factors associated with cognitive decline highlighted several issues that made drawing firm conclusions from the available evidence difficult. The definitions and assessments of cognitive decline were not standardized across studies, which limited quantitative synthesis of the data. Also, validation of the type and degree of exposure was limited or absent for many of the factors. When significant differences were noted, the magnitude of the actual differences in outcomes between the exposed and unexposed groups were often small and were evident for only a small portion of the many cognitive measures. In addition, the cognitive measures associated with decline differed across studies.

Evidence From Observational Studies

We found few consistent risk or protective associations from the observational studies (Tables 1 and 2). Summary estimates of the strength of the association were available only for tobacco use and diabetes. A systematic review on tobacco use (175) included a meta-analysis on 3 studies that used a predetermined threshold to define cognitive decline on the MMSE. Current smokers were more likely to exhibit cognitive decline than former smokers or nonsmokers (relative risk, 1.41 [95% CI, 1.16 to 1.71]). A systematic review on diabetes (17) included a meta-analysis on 6 studies that used either the MMSE or the Modified MMSE, with follow-up that ranged from 2 to 6 years. The 6 studies used different predetermined definitions of cognitive decline on these tests. Diabetic persons were more likely than nondiabetic persons to show cognitive decline on the MMSE (odds ratio, 1.2 [CI, 1.05 to 1.4]). Among the other studies on diabetes that we identified, findings on specific cognitive functions differed. For example, one study (20) reported a diabetes-associated decline on tests of verbal memory and processing speed, whereas another study (21) reported no association between diabetes and verbal memory or processing speed but did find that verbal fluency decreased more among diabetic persons than nondiabetic persons. Other factors that showed a likely association with increased risk for cognitive decline were the apolipoprotein E ε4 allele, depressive symptoms, and the metabolic syndrome. Factors probably associated with a lower risk for cognitive decline were involvement in cognitive, physical, or other leisure activities and dietary factors, such as a Mediterranean diet or vegetable or ω-3 fatty acid intake. For most factors associated with cognitive decline, the strength of the association represented by relative risks or hazard ratios were generally in the range of 0.6 to 1.6, often with CIs that approached 1.0.

Evidence From RCTs

Table 2 shows that few RCTs assessed the effects of the various factors on cognitive decline. Some of the RCTs for vitamins B, C, and E and folate; antihypertensive drugs; statins; and nonsteroidal anti-inflammatory drugs added cognitive measures as secondary outcomes, often after the start of the trial. Although one of the aims with this key question was to determine whether interventions had a differential effect among subgroups, the few RCTs we identified reported no information on differential outcomes by subgroups.
Trial data showed an effect on cognitive decline from only 2 factors. Of these factors, the trial on cognitive training (176) concluded that domain-specific training was beneficial for maintaining cognition for the targeted domain. At 2 years after the intervention, the effect sizes for cognitive training, calculated as the difference in composite domain-specific mean performance of the groups divided by the intraparticipant SD, were 0.17 for memory (P < 0.001), 0.26 for reasoning (P < 0.001), and 0.87 for speed of processing (P < 0.001). These modest benefits remained at the 5-year follow-up. A single RCT (173) with 170 participants examined an intervention of physical exercise and reported that at 18 months (12 months after treatment), the treatment group showed a decrease of 0.73 point (CI, −1.27 to 0.03 point) on the 70-point Alzheimer's Disease Assessment Scale–Cognitive Subscale (lower scores indicate better performance). The control group showed a decrease of 0.04 point (CI, −0.46 to 0.88 point). The repeated measures analysis of covariance across the 6-, 12-, and 18-month follow-ups showed statistically significant improvement in the exercise group (P = 0.04). Observational studies for some factors, such as ω-3 fatty acids, the Mediterranean diet, vegetable intake, and some leisure activities, suggested a decreased risk for cognitive decline. However, RCT data on these factors are limited to absent and have no GRADE elements (such as a dose–response relationship) to strengthen the confidence in the association, so the quality of evidence for these factors is low.

Evidence for the 2 Key Questions Combined

The results from observational studies and RCTs were discrepant for some factors. For example, the observational studies on ω-3 fatty acids suggested a decreased risk for cognitive decline with higher levels of ω-3 fatty acids, but the single short-term RCT for this factor showed no effect of ω-3 fatty acids on cognitive decline.
To synthesize all evidence for a factor, we reviewed the combined observational and RCT evidence and assigned an overall GRADE quality rating for each factor (Table 3). We rated the evidence for most factors as low-quality, but we note that the quality of evidence may vary substantially even within a given rating level; for example, it varies considerably within the low-quality level. We also note that low-quality evidence indicates that additional research is likely to alter the point estimate or direction of association of a factor with an outcome and is not a statement about how an individual study was designed or performed.

Table 3.

Summary of Findings on Potential Risk Factors and Interventions for Cognitive Decline

Table 3.
We found high-quality evidence for only 1 factor's effect on cognitive decline. Cognitive training on processing speed or reasoning showed a decreased risk for cognitive decline in the specific targeted cognitive abilities over a 2-year follow-up, and the evidence was rated as high-quality primarily on the basis of 1 RCT (176). Observational studies of self-reported engagement in cognitively stimulating activities suggest an association with less cognitive decline, but this exposure is probably different from the cognitive training used in the RCT. Several factors showed no association with cognitive decline, based on evidence that ranged from low- to high-quality. Table 3 also lists several factors for which the evidence was inadequate to assess the presence of an association. We reached this conclusion if no studies or too few studies had been done on the factor or if the exposure or outcome measures for the studies were too discrepant to synthesize the results.

Discussion

We conducted this systematic review to summarize the evidence on factors associated with cognitive decline and the therapeutic and adverse effects of interventions to maintain cognitive function. Among the extensive list of putative risk or protective factors we reviewed, few had sufficient evidence from which to draw firm conclusions about their association with cognitive decline. This does not mean that the remaining factors do not play a role in cognitive function in later life, but only that evidence was insufficient to draw such a conclusion.
Cognitive decline in later life has numerous causes, and each may be associated with different risk or protective factors. In addition, some persons initially identified as mildly impaired revert to normal cognition on follow-up assessment. Grouping together all persons with cognitive decline may dilute associations linked with specific subtypes of cognitive decline. In the studies we reviewed, different definitions of cognitive decline made comparisons across studies difficult; some studies used incident MCI or cognitive impairment without dementia as the outcome, whereas others used arbitrary categories of decline on cognitive measures or continuous measures of cognitive decline. Because of the lack of standardization across outcome measures, we focused on studies with categorical outcome measures when the studies with continuous outcome measures showed results consistent with those that used categorical measures. Quantitative synthesis of studies that used continuous outcome measures may provide greater sensitivity to detect group differences than categorical outcomes, but the clinical importance of these differences may be unclear. Future studies need more standardization at various steps of the research process before all available data can be synthesized. However, standardization has its weaknesses and may limit innovations that advance science. The key is to strike a balance between methods that are sufficiently uniform to maximize the use of study results and those that are novel enough to advance the field to the next level.
Issues related to age are central to the interpretation of these results. The incidence of Alzheimer disease increases markedly with age, doubling in rate approximately every 5 years. Cognitive decline is often a prodromal symptom of Alzheimer disease. The older the sample, the more likely that cognitive decline represents prodromal Alzheimer disease, and thus such factors as depression, physical exercise, and cognitive activities that were associated with cognitive decline may actually be a symptom or correlate of Alzheimer disease. Age is also likely to be a key issue with regard to the timing of the exposure. We examined exposures that spanned from childhood to late life. Exposures may influence risk for cognitive decline during certain times. Ideally, the exposure should be measured in different age groups within the same study to control for interstudy variability in measurement, but this may not be realistic because of the long follow-up necessary when studying midlife exposures.
Interventions may also have different effects at different points throughout life or the cognitive decline process. Using an example from the Alzheimer disease intervention literature, hormone replacement therapy has not been shown to lower risk for Alzheimer disease, but the large RCTs on hormone replacement therapy have been conducted in women 65 years or older. It is unknown whether hormone replacement therapy may have cognitive benefits in younger women who are closer to menopause. Although interventions or lifestyle modifications should presumably be done as early as possible, a given intervention may exert its effect during other times in a person's life. Careful consideration of the complex relationships among exposure, age, and disease will be fundamental to understanding the factors that alter risk for cognitive decline.
Our review of the research on this topic indicated several limitations in the extant literature. We have mentioned some of these issues in the Results section, but additional points deserve mention. Epidemiologic studies of complex diseases that use observational data often simultaneously evaluate the association between a range of exposures and the outcome of interest. These studies do not typically make their analyses specific to 1 or 2 factors of interest. How this approach may influence the association between the factor of interest and the outcome is unknown, but we note the issue as one to be considered when interpreting results. Another area of uncertainty relates to how exposure is defined. Studies did not define whether exposure levels were determined a priori, linked to biological rationale or clinical relevance, or informed by previous studies. In addition, the relatively modest effect reported in many studies raised questions about the robustness of the results, concerns about statistical versus clinical significance, and the possibility of residual confounding. The failure of some studies to overtly exclude persons with cognitive impairment or dementia at baseline also complicated our interpretation of the results. Given the small difference in the outcome measures between the exposed and unexposed groups, persons with prodromal or mild dementia may account for some of a factor's association with cognitive decline if that factor is also an early symptom of dementia (for example, depressive symptoms or decreased participation in cognitively engaging activities). Finally, information about the statistical power of samples was typically lacking, so when null findings were reported, questions remained about whether the study was adequately powered to detect a difference.
The preferred research design for investigating potential interventions is an RCT. However, because many potential interventions will be difficult to evaluate in trials, efforts to obtain quality evidence on these factors require well-designed observational studies. In addition, many of the exposures we reviewed probably affect the risk for cognitive decline in combination with other factors, not in isolation. For example, it is not realistic to isolate one nutritional component from others; one factor, such as physical exercise or cognitively stimulating leisure activities, from others that may also be part of a healthier lifestyle; or medical conditions from their treatments. Thus, ideal future interventions would be multidimensional, combine interventions for multiple risk factors, and control for many other factors. Many of the factors that are not amenable to interventions are exposures that one would want to avoid because of their negative effect on outcomes other than cognition, such as smoking, diabetes, hypertension, and few years of education. These and other factors may be most appropriately addressed through public policy interventions (such as educational campaigns or community designs that promote physical activity) and public health interventions (such as educational campaigns that promote a healthy diet).
Our review has limitations. By excluding RCTs with sample sizes of fewer than 50 participants and observational studies with fewer than 300 participants, we may have missed some important evidence, particularly for factors with scant data. By excluding RCTs that lasted for less than 1 year, we may have missed some studies that showed promising short-term results. These studies would not have been adequate to conclude that the intervention was useful for preventing cognitive decline, but they may have provided the impetus to conduct longer trials. The scarcity of articles that used similar cognitive measures precluded any efforts to pool findings statistically. Finally, although our search strategies were similar to those used in other systematic reviews, this is a difficult body of literature to search, and we may have overlooked relevant studies.
In summary, critical improvements in research methods are needed, such as precise, better validated, and more standard exposure measures; more standardized cognitive assessment measures across studies; and studies of longer duration. Studies should also take into account the intensity, duration, and timing of the exposure, because exposures may be more influential and interventions more effective during critical or sensitive periods throughout life. The current literature does not provide adequate evidence to make recommendations for interventions. Previous work has provided a few potential leads, such as cognitive training, physical exercise, and some nutritional patterns. These should now be pursued with potentially novel approaches and increasingly rigorous scientific methods to identify a real signal among the numerous factors throughout the life course that may contribute to complex, late-life cognitive disorders.

References

  1. Yu
    W
    ,  
    Clyne
    M
    ,  
    Khoury
    MJ
    ,  
    Gwinn
    M
    .  
    Phenopedia and Genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associations.
    Bioinformatics
    2010
    26
    145
    6
     PubMed
    CrossRef
  2. Bertram
    L
    ,  
    McQueen
    MB
    ,  
    Mullin
    K
    ,  
    Blacker
    D
    ,  
    Tanzi
    RE
    .  
    Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database.
    Nat Genet
    2007
    39
    17
    23
     PubMed
  3. .  Guyatt G, Rennie D, Meade MO, Cook DJ
    User's Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. 2nd ed.
    New York
    McGraw-Hill
    2008
  4. Agency for Healthcare Research and Quality. Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews, Version 1.0 [Draft posted October 2007]. Rockville, MD: Agency for Healthcare Research and Quality; 2007. Accessed athttp://effectivehealthcare.ahrq.gov/repFiles/2007_10DraftMethodsGuide.pdfon 27 May 2010.
  5. Wang C, Chung M, Balk E, Kupelnick B, DeVine D, Lawrence A, et al. Effects of Omega-3 Fatty Acids on Cardiovascular Disease. Evidence Report/Technology Assessment No. 94. AHRQ Publication No. 04-E009-2. Rockville, MD: Agency for Healthcare Research and Quality; 2004. Accessed atwww.ahrq.gov/downloads/pub/evidence/pdf/o3cardio/o3cardio.pdfon 27 May 2010.
  6. Myers ER, McCrory DC, Mills AA, Price TM, Swamy GK, Tantibhedhyangkul J, et al. Effectiveness of Assisted Reproductive Technology. Evidence Report/Technology Assessment No. 167. AHRQ Publication No. 08-E012. Rockville, MD: Agency for Healthcare Research and Quality; 2008. Accessed atwww.ahrq.gov/downloads/pub/evidence/pdf/infertility/infertility.pdfon 27 May 2010.
  7. Williams
    JW
    ,  
    Plassman
    BL
    ,  
    Burke
    J
    ,  
    Holsinger
    T
    ,  
    Benjamin
    S
    .  
    Preventing Alzheimer's Disease and Cognitive Decline. Evidence Report/Technology Assessment No. 193.
    Rockville, MD
    Agency for Healthcare Research and Quality
    2010
  8. Morris
    MC
    ,  
    Evans
    DA
    ,  
    Bienias
    JL
    ,  
    Tangney
    CC
    ,  
    Wilson
    RS
    .  
    Dietary fat intake and 6-year cognitive change in an older biracial community population.
    Neurology
    2004
    62
    1573
    9
     PubMed
  9. Berr
    C
    ,  
    Balansard
    B
    ,  
    Arnaud
    J
    ,  
    Roussel
    AM
    ,  
    Alpérovitch
    A
    .  
    Cognitive decline is associated with systemic oxidative stress: the EVA study. Etude du Vieillissement Artériel.
    J Am Geriatr Soc
    2000
    48
    1285
    91
     PubMed
  10. Morris
    MC
    ,  
    Evans
    DA
    ,  
    Tangney
    CC
    ,  
    Bienias
    JL
    ,  
    Schneider
    JA
    ,  
    Wilson
    RS
    .  
    et al.
    Dietary copper and high saturated and trans fat intakes associated with cognitive decline.
    Arch Neurol
    2006
    63
    1085
    8
     PubMed
  11. Akbaraly
    TN
    ,  
    Akbaraly
    NT
    ,  
    Hininger-Favier
    I
    ,  
    Carrière
    I
    ,  
    Arnaud
    J
    ,  
    Gourlet
    V
    .  
    et al.
    Plasma selenium over time and cognitive decline in the elderly.
    Epidemiology
    2007
    18
    52
    8
     PubMed
  12. Scarmeas
    N
    ,  
    Stern
    Y
    ,  
    Mayeux
    R
    ,  
    Manly
    JJ
    ,  
    Schupf
    N
    ,  
    Luchsinger
    JA
    .  
    Mediterranean diet and mild cognitive impairment.
    Arch Neurol
    2009
    66
    216
    25
     PubMed
  13. Féart
    C
    ,  
    Samieri
    C
    ,  
    Rondeau
    V
    ,  
    Amieva
    H
    ,  
    Portet
    F
    ,  
    Dartigues
    JF
    .  
    et al.
    Adherence to a Mediterranean diet, cognitive decline, and risk of dementia.
    JAMA
    2009
    302
    638
    48
     PubMed
  14. Kang
    JH
    ,  
    Ascherio
    A
    ,  
    Grodstein
    F
    .  
    Fruit and vegetable consumption and cognitive decline in aging women.
    Ann Neurol
    2005
    57
    713
    20
     PubMed
  15. Morris
    MC
    ,  
    Evans
    DA
    ,  
    Tangney
    CC
    ,  
    Bienias
    JL
    ,  
    Wilson
    RS
    .  
    Associations of vegetable and fruit consumption with age-related cognitive change.
    Neurology
    2006
    67
    1370
    6
     PubMed
  16. Lu
    FP
    ,  
    Lin
    KP
    ,  
    Kuo
    HK
    .  
    Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis.
    PLoS One
    2009
    4
    4144
     PubMed
  17. Cukierman
    T
    ,  
    Gerstein
    HC
    ,  
    Williamson
    JD
    .  
    Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies.
    Diabetologia
    2005
    48
    2460
    9
     PubMed
  18. Cherbuin
    N
    ,  
    Reglade-Meslin
    C
    ,  
    Kumar
    R
    ,  
    Jacomb
    P
    ,  
    Easteal
    S
    ,  
    Christensen
    H
    .  
    et al.
    Risk factors of transition from normal cognition to mild cognitive disorder: the PATH through Life Study.
    Dement Geriatr Cogn Disord
    2009
    28
    47
    55
     PubMed
  19. Yaffe
    K
    ,  
    Fiocco
    AJ
    ,  
    Lindquist
    K
    ,  
    Vittinghoff
    E
    ,  
    Simonsick
    EM
    ,  
    Newman
    AB
    .  
    et al.
    Health ABC Study
    Predictors of maintaining cognitive function in older adults: the Health ABC study.
    Neurology
    2009
    72
    2029
    35
     PubMed
  20. Comijs
    HC
    ,  
    Kriegsman
    DM
    ,  
    Dik
    MG
    ,  
    Deeg
    DJ
    ,  
    Jonker
    C
    ,  
    Stalman
    WA
    .  
    Somatic chronic diseases and 6-year change in cognitive functioning among older persons.
    Arch Gerontol Geriatr
    2009
    48
    191
    6
     PubMed
  21. Knopman
    DS
    ,  
    Mosley
    TH
    ,  
    Catellier
    DJ
    ,  
    Coker
    LH
    .  
    Atherosclerosis Risk in Communities Study Brain MRI Study
    Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study.
    Alzheimers Dement
    2009
    5
    207
    14
     PubMed
  22. Devore
    EE
    ,  
    Kang
    JH
    ,  
    Okereke
    O
    ,  
    Grodstein
    F
    .  
    Physical activity levels and cognition in women with type 2 diabetes.
    Am J Epidemiol
    2009
    170
    1040
    7
     PubMed
  23. Logroscino
    G
    ,  
    Kang
    JH
    ,  
    Grodstein
    F
    .  
    Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years.
    BMJ
    2004
    328
    548
     PubMed
  24. Nguyen
    HT
    ,  
    Black
    SA
    ,  
    Ray
    LA
    ,  
    Espino
    DV
    ,  
    Markides
    KS
    .  
    Predictors of decline in MMSE scores among older Mexican Americans.
    J Gerontol A Biol Sci Med Sci
    2002
    57
    M181
    5
     PubMed
  25. Stewart
    R
    ,  
    Prince
    M
    ,  
    Mann
    A
    .  
    Age, vascular risk, and cognitive decline in an older, British, African-Caribbean population.
    J Am Geriatr Soc
    2003
    51
    1547
    53
     PubMed
  26. Wu
    JH
    ,  
    Haan
    MN
    ,  
    Liang
    J
    ,  
    Ghosh
    D
    ,  
    Gonzalez
    HM
    ,  
    Herman
    WH
    .  
    Impact of diabetes on cognitive function among older Latinos: a population-based cohort study.
    J Clin Epidemiol
    2003
    56
    686
    93
     PubMed
  27. Wu
    JH
    ,  
    Haan
    MN
    ,  
    Liang
    J
    ,  
    Ghosh
    D
    ,  
    Gonzalez
    HM
    ,  
    Herman
    WH
    .  
    Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study.
    Ann Epidemiol
    2003
    13
    369
    76
     PubMed
  28. Yaffe
    K
    ,  
    Kanaya
    A
    ,  
    Lindquist
    K
    ,  
    Simonsick
    EM
    ,  
    Harris
    T
    ,  
    Shorr
    RI
    .  
    et al.
    The metabolic syndrome, inflammation, and risk of cognitive decline.
    JAMA
    2004
    292
    2237
    42
     PubMed
  29. van den Berg
    E
    ,  
    Biessels
    GJ
    ,  
    de Craen
    AJ
    ,  
    Gussekloo
    J
    ,  
    Westendorp
    RG
    .  
    The metabolic syndrome is associated with decelerated cognitive decline in the oldest old.
    Neurology
    2007
    69
    979
    85
     PubMed
  30. Ho
    RC
    ,  
    Niti
    M
    ,  
    Yap
    KB
    ,  
    Kua
    EH
    ,  
    Ng
    TP
    .  
    Metabolic syndrome and cognitive decline in chinese older adults: results from the singapore longitudinal ageing studies.
    Am J Geriatr Psychiatry
    2008
    16
    519
    22
     PubMed
  31. Shah
    RC
    ,  
    Wilson
    RS
    ,  
    Bienias
    JL
    ,  
    Arvanitakis
    Z
    ,  
    Evans
    DA
    ,  
    Bennett
    DA
    .  
    Relation of blood pressure to risk of incident Alzheimer's disease and change in global cognitive function in older persons.
    Neuroepidemiology
    2006
    26
    30
    6
     PubMed
  32. Peila
    R
    ,  
    White
    LR
    ,  
    Masaki
    K
    ,  
    Petrovitch
    H
    ,  
    Launer
    LJ
    .  
    Reducing the risk of dementia: efficacy of long-term treatment of hypertension.
    Stroke
    2006
    37
    1165
    70
     PubMed
  33. Carmelli
    D
    ,  
    Swan
    GE
    ,  
    Reed
    T
    ,  
    Miller
    B
    ,  
    Wolf
    PA
    ,  
    Jarvik
    GP
    .  
    et al.
    Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins.
    Neurology
    1998
    50
    1580
    5
     PubMed
  34. Tervo
    S
    ,  
    Kivipelto
    M
    ,  
    Hänninen
    T
    ,  
    Vanhanen
    M
    ,  
    Hallikainen
    M
    ,  
    Mannermaa
    A
    .  
    et al.
    Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects.
    Dement Geriatr Cogn Disord
    2004
    17
    196
    203
     PubMed
  35. Reitz
    C
    ,  
    Tang
    MX
    ,  
    Manly
    J
    ,  
    Mayeux
    R
    ,  
    Luchsinger
    JA
    .  
    Hypertension and the risk of mild cognitive impairment.
    Arch Neurol
    2007
    64
    1734
    40
     PubMed
  36. Alves de Moraes
    S
    ,  
    Szklo
    M
    ,  
    Knopman
    D
    ,  
    Sato
    R
    .  
    The relationship between temporal changes in blood pressure and changes in cognitive function: atherosclerosis risk in communities (ARIC) study.
    Prev Med
    2002
    35
    258
    63
     PubMed
  37. Knopman
    D
    ,  
    Boland
    LL
    ,  
    Mosley
    T
    ,  
    Howard
    G
    ,  
    Liao
    D
    ,  
    Szklo
    M
    .  
    et al.
    Atherosclerosis Risk in Communities (ARIC) Study Investigators
    Cardiovascular risk factors and cognitive decline in middle-aged adults.
    Neurology
    2001
    56
    42
    8
     PubMed
  38. Barnes
    DE
    ,  
    Cauley
    JA
    ,  
    Lui
    LY
    ,  
    Fink
    HA
    ,  
    McCulloch
    C
    ,  
    Stone
    KL
    .  
    et al.
    Women who maintain optimal cognitive function into old age.
    J Am Geriatr Soc
    2007
    55
    259
    64
     PubMed
  39. Swan
    GE
    ,  
    DeCarli
    C
    ,  
    Miller
    BL
    ,  
    Reed
    T
    ,  
    Wolf
    PA
    ,  
    Jack
    LM
    .  
    et al.
    Association of midlife blood pressure to late-life cognitive decline and brain morphology.
    Neurology
    1998
    51
    986
    93
     PubMed
  40. Gurland
    BJ
    ,  
    Teresi
    J
    ,  
    Smith
    WM
    ,  
    Black
    D
    ,  
    Hughes
    G
    ,  
    Edlavitch
    S
    .  
    Effects of treatment for isolated systolic hypertension on cognitive status and depression in the elderly.
    J Am Geriatr Soc
    1988
    36
    1015
    22
     PubMed
  41. Hebert
    LE
    ,  
    Scherr
    PA
    ,  
    Bennett
    DA
    ,  
    Bienias
    JL
    ,  
    Wilson
    RS
    ,  
    Morris
    MC
    .  
    et al.
    Blood pressure and late-life cognitive function change: a biracial longitudinal population study.
    Neurology
    2004
    62
    2021
    4
     PubMed
  42. Insel
    KC
    ,  
    Palmer
    RF
    ,  
    Stroup-Benham
    CA
    ,  
    Markides
    KS
    ,  
    Espino
    DV
    .  
    Association between change in systolic blood pressure and cognitive decline among elderly Mexican Americans: data from the Hispanic established population for epidemiology study of the elderly.
    Exp Aging Res
    2005
    31
    35
    54
     PubMed
  43. Kuo
    HK
    ,  
    Jones
    RN
    ,  
    Milberg
    WP
    ,  
    Tennstedt
    S
    ,  
    Talbot
    L
    ,  
    Morris
    JN
    .  
    et al.
    Effect of blood pressure and diabetes mellitus on cognitive and physical functions in older adults: a longitudinal analysis of the advanced cognitive training for independent and vital elderly cohort.
    J Am Geriatr Soc
    2005
    53
    1154
    61
     PubMed
  44. Tzourio
    C
    ,  
    Dufouil
    C
    ,  
    Ducimetière
    P
    ,  
    Alpérovitch
    A
    .  
    Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging.
    Neurology
    1999
    53
    1948
    52
     PubMed
  45. Waldstein
    SR
    ,  
    Giggey
    PP
    ,  
    Thayer
    JF
    ,  
    Zonderman
    AB
    .  
    Nonlinear relations of blood pressure to cognitive function: the Baltimore Longitudinal Study of Aging.
    Hypertension
    2005
    45
    374
    9
     PubMed
  46. Glynn
    RJ
    ,  
    Beckett
    LA
    ,  
    Hebert
    LE
    ,  
    Morris
    MC
    ,  
    Scherr
    PA
    ,  
    Evans
    DA
    .  
    Current and remote blood pressure and cognitive decline.
    JAMA
    1999
    281
    438
    45
     PubMed
  47. Anstey
    KJ
    ,  
    Lipnicki
    DM
    ,  
    Low
    LF
    .  
    Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis.
    Am J Geriatr Psychiatry
    2008
    16
    343
    54
     PubMed
  48. Packard
    CJ
    ,  
    Westendorp
    RG
    ,  
    Stott
    DJ
    ,  
    Caslake
    MJ
    ,  
    Murray
    HM
    ,  
    Shepherd
    J
    .  
    et al.
    Prospective Study of Pravastatin in the Elderly at Risk Group
    Association between apolipoprotein E4 and cognitive decline in elderly adults.
    J Am Geriatr Soc
    2007
    55
    1777
    85
     PubMed
  49. Luchsinger
    JA
    ,  
    Tang
    MX
    ,  
    Shea
    S
    ,  
    Miller
    J
    ,  
    Green
    R
    ,  
    Mayeux
    R
    .  
    Plasma homocysteine levels and risk of Alzheimer disease.
    Neurology
    2004
    62
    1972
    6
     PubMed
  50. Kado
    DM
    ,  
    Karlamangla
    AS
    ,  
    Huang
    MH
    ,  
    Troen
    A
    ,  
    Rowe
    JW
    ,  
    Selhub
    J
    .  
    et al.
    Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging.
    Am J Med
    2005
    118
    161
    7
     PubMed
  51. Dufouil
    C
    ,  
    Alpérovitch
    A
    ,  
    Ducros
    V
    ,  
    Tzourio
    C
    .  
    Homocysteine, white matter hyperintensities, and cognition in healthy elderly people.
    Ann Neurol
    2003
    53
    214
    21
     PubMed
  52. Kalmijn
    S
    ,  
    Launer
    LJ
    ,  
    Lindemans
    J
    ,  
    Bots
    ML
    ,  
    Hofman
    A
    ,  
    Breteler
    MM
    .  
    Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study.
    Am J Epidemiol
    1999
    150
    283
    9
     PubMed
  53. Clarke
    R
    ,  
    Birks
    J
    ,  
    Nexo
    E
    ,  
    Ueland
    PM
    ,  
    Schneede
    J
    ,  
    Scott
    J
    .  
    et al.
    Low vitamin B-12 status and risk of cognitive decline in older adults.
    Am J Clin Nutr
    2007
    86
    1384
    91
     PubMed
  54. Sturman
    MT
    ,  
    de Leon
    CF
    ,  
    Bienias
    JL
    ,  
    Morris
    MC
    ,  
    Wilson
    RS
    ,  
    Evans
    DA
    .  
    Body mass index and cognitive decline in a biracial community population.
    Neurology
    2008
    70
    360
    7
     PubMed
  55. Barnes
    DE
    ,  
    Alexopoulos
    GS
    ,  
    Lopez
    OL
    ,  
    Williamson
    JD
    ,  
    Yaffe
    K
    .  
    Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study.
    Arch Gen Psychiatry
    2006
    63
    273
    9
     PubMed
  56. Christensen
    H
    ,  
    Henderson
    AS
    ,  
    Korten
    AE
    ,  
    Jorm
    AF
    ,  
    Jacomb
    PA
    ,  
    Mackinnon
    AJ
    .  
    ICD-10 mild cognitive disorder: its outcome three years later.
    Int J Geriatr Psychiatry
    1997
    12
    581
    6
     PubMed
  57. Dufouil
    C
    ,  
    Fuhrer
    R
    ,  
    Dartigues
    JF
    ,  
    Alpérovitch
    A
    .  
    Longitudinal analysis of the association between depressive symptomatology and cognitive deterioration.
    Am J Epidemiol
    1996
    144
    634
    41
     PubMed
  58. Geda
    YE
    ,  
    Knopman
    DS
    ,  
    Mrazek
    DA
    ,  
    Jicha
    GA
    ,  
    Smith
    GE
    ,  
    Negash
    S
    .  
    et al.
    Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study.
    Arch Neurol
    2006
    63
    435
    40
     PubMed
  59. Geerlings
    MI
    ,  
    Schoevers
    RA
    ,  
    Beekman
    AT
    ,  
    Jonker
    C
    ,  
    Deeg
    DJ
    ,  
    Schmand
    B
    .  
    et al.
    Depression and risk of cognitive decline and Alzheimer's disease. Results of two prospective community-based studies in The Netherlands.
    Br J Psychiatry
    2000
    176
    568
    75
     PubMed
  60. Ng
    TP
    ,  
    Niti
    M
    ,  
    Zaw
    MH
    ,  
    Kua
    EH
    .  
    Depressive symptoms and incident cognitive impairment in cognitively well-functioning older men and women.
    J Am Geriatr Soc
    2009
    57
    1058
    63
     PubMed
  61. Panza
    F
    ,  
    D'Introno
    A
    ,  
    Colacicco
    AM
    ,  
    Capurso
    C
    ,  
    Del Parigi
    A
    ,  
    Caselli
    RJ
    .  
    et al.
    Italian Longitudinal Study on Aging Working Group
    Depressive symptoms, vascular risk factors and mild cognitive impairment. The Italian longitudinal study on aging.
    Dement Geriatr Cogn Disord
    2008
    25
    336
    46
     PubMed
  62. Paterniti
    S
    ,  
    Verdier-Taillefer
    MH
    ,  
    Dufouil
    C
    ,  
    Alpérovitch
    A
    .  
    Depressive symptoms and cognitive decline in elderly people. Longitudinal study.
    Br J Psychiatry
    2002
    181
    406
    10
     PubMed
  63. Ravaglia
    G
    ,  
    Forti
    P
    ,  
    Lucicesare
    A
    ,  
    Rietti
    E
    ,  
    Pisacane
    N
    ,  
    Mariani
    E
    .  
    et al.
    Prevalent depressive symptoms as a risk factor for conversion to mild cognitive impairment in an elderly Italian cohort.
    Am J Geriatr Psychiatry
    2008
    16
    834
    43
     PubMed
  64. Wilson
    RS
    ,  
    Schneider
    JA
    ,  
    Boyle
    PA
    ,  
    Arnold
    SE
    ,  
    Tang
    Y
    ,  
    Bennett
    DA
    .  
    Chronic distress and incidence of mild cognitive impairment.
    Neurology
    2007
    68
    2085
    92
     PubMed
  65. Yaffe
    K
    ,  
    Blackwell
    T
    ,  
    Gore
    R
    ,  
    Sands
    L
    ,  
    Reus
    V
    ,  
    Browner
    WS
    .  
    Depressive symptoms and cognitive decline in nondemented elderly women: a prospective study.
    Arch Gen Psychiatry
    1999
    56
    425
    30
     PubMed
  66. Bierman
    EJ
    ,  
    Comijs
    HC
    ,  
    Rijmen
    F
    ,  
    Jonker
    C
    ,  
    Beekman
    AT
    .  
    Anxiety symptoms and cognitive performance in later life: results from the longitudinal aging study Amsterdam.
    Aging Ment Health
    2008
    12
    517
    23
     PubMed
  67. Gallacher
    J
    ,  
    Bayer
    A
    ,  
    Fish
    M
    ,  
    Pickering
    J
    ,  
    Pedro
    S
    ,  
    Dunstan
    F
    .  
    et al.
    Does anxiety affect risk of dementia? Findings from the Caerphilly Prospective Study.
    Psychosom Med
    2009
    71
    659
    66
     PubMed
  68. Wetherell
    JL
    ,  
    Reynolds
    CA
    ,  
    Gatz
    M
    ,  
    Pedersen
    NL
    .  
    Anxiety, cognitive performance, and cognitive decline in normal aging.
    J Gerontol B Psychol Sci Soc Sci
    2002
    57
    P246
    55
     PubMed
  69. Wilson
    RS
    ,  
    Scherr
    PA
    ,  
    Hoganson
    G
    ,  
    Bienias
    JL
    ,  
    Evans
    DA
    ,  
    Bennett
    DA
    .  
    Early life socioeconomic status and late life risk of Alzheimer's disease.
    Neuroepidemiology
    2005
    25
    8
    14
     PubMed
  70. Everson-Rose
    SA
    ,  
    Mendes de Leon
    CF
    ,  
    Bienias
    JL
    ,  
    Wilson
    RS
    ,  
    Evans
    DA
    .  
    Early life conditions and cognitive functioning in later life.
    Am J Epidemiol
    2003
    158
    1083
    9
     PubMed
  71. Graves
    AB
    ,  
    Rajaram
    L
    ,  
    Bowen
    JD
    ,  
    McCormick
    WC
    ,  
    McCurry
    SM
    ,  
    Larson
    EB
    .  
    Cognitive decline and Japanese culture in a cohort of older Japanese Americans in King County, WA: the Kame Project.
    J Gerontol B Psychol Sci Soc Sci
    1999
    54
    S154
    61
     PubMed
  72. Tyas
    SL
    ,  
    Salazar
    JC
    ,  
    Snowdon
    DA
    ,  
    Desrosiers
    MF
    ,  
    Riley
    KP
    ,  
    Mendiondo
    MS
    .  
    et al.
    Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study.
    Am J Epidemiol
    2007
    165
    1231
    8
     PubMed
  73. Alvarado
    BE
    ,  
    Zunzunegui
    MV
    ,  
    DelSer
    T
    ,  
    Béland
    F
    .  
    Cognitive decline is related to education and occupation in a Spanish elderly cohort.
    Aging Clin Exp Res
    2002
    14
    132
    42
     PubMed
  74. Koster
    A
    ,  
    Penninx
    BW
    ,  
    Bosma
    H
    ,  
    Kempen
    GI
    ,  
    Newman
    AB
    ,  
    Rubin
    SM
    .  
    et al.
    Socioeconomic differences in cognitive decline and the role of biomedical factors.
    Ann Epidemiol
    2005
    15
    564
    71
     PubMed
  75. Lee
    S
    ,  
    Buring
    JE
    ,  
    Cook
    NR
    ,  
    Grodstein
    F
    .  
    The relation of education and income to cognitive function among professional women.
    Neuroepidemiology
    2006
    26
    93
    101
     PubMed
  76. Lee
    S
    ,  
    Kawachi
    I
    ,  
    Berkman
    LF
    ,  
    Grodstein
    F
    .  
    Education, other socioeconomic indicators, and cognitive function.
    Am J Epidemiol
    2003
    157
    712
    20
     PubMed
  77. Kalmijn
    S
    ,  
    Feskens
    EJ
    ,  
    Launer
    LJ
    ,  
    Kromhout
    D
    .  
    Longitudinal study of the effect of apolipoprotein e4 allele on the association between education and cognitive decline in elderly men.
    BMJ
    1997
    314
    34
    5
     PubMed
  78. Manly
    JJ
    ,  
    Schupf
    N
    ,  
    Tang
    MX
    ,  
    Stern
    Y
    .  
    Cognitive decline and literacy among ethnically diverse elders.
    J Geriatr Psychiatry Neurol
    2005
    18
    213
    7
     PubMed
  79. Wilson
    RS
    ,  
    Hebert
    LE
    ,  
    Scherr
    PA
    ,  
    Barnes
    LL
    ,  
    Mendes de Leon
    CF
    ,  
    Evans
    DA
    .  
    Educational attainment and cognitive decline in old age.
    Neurology
    2009
    72
    460
    5
     PubMed
  80. Karlamangla
    AS
    ,  
    Miller-Martinez
    D
    ,  
    Aneshensel
    CS
    ,  
    Seeman
    TE
    ,  
    Wight
    RG
    ,  
    Chodosh
    J
    .  
    Trajectories of cognitive function in late life in the United States: demographic and socioeconomic predictors.
    Am J Epidemiol
    2009
    170
    331
    42
     PubMed
  81. Shadlen
    MF
    ,  
    Larson
    EB
    ,  
    Wang
    L
    ,  
    Phelan
    EA
    ,  
    McCormick
    WC
    ,  
    Jolley
    L
    .  
    et al.
    Education modifies the effect of apolipoprotein epsilon 4 on cognitive decline.
    Neurobiol Aging
    2005
    26
    17
    24
     PubMed
  82. Christensen
    H
    ,  
    Batterham
    PJ
    ,  
    Mackinnon
    AJ
    ,  
    Jorm
    AF
    ,  
    Mack
    HA
    ,  
    Mather
    KA
    .  
    et al.
    The association of APOE genotype and cognitive decline in interaction with risk factors in a 65-69 year old community sample.
    BMC Geriatr
    2008
    8
    14
     PubMed
  83. Winnock
    M
    ,  
    Letenneur
    L
    ,  
    Jacqmin-Gadda
    H
    ,  
    Dallongeville
    J
    ,  
    Amouyel
    P
    ,  
    Dartigues
    JF
    .  
    Longitudinal analysis of the effect of apolipoprotein E epsilon4 and education on cognitive performance in elderly subjects: the PAQUID study.
    J Neurol Neurosurg Psychiatry
    2002
    72
    794
    7
     PubMed
  84. Potter
    GG
    ,  
    Plassman
    BL
    ,  
    Helms
    MJ
    ,  
    Foster
    SM
    ,  
    Edwards
    NW
    .  
    Occupational characteristics and cognitive performance among elderly male twins.
    Neurology
    2006
    67
    1377
    82
     PubMed
  85. Virtanen
    M
    ,  
    Singh-Manoux
    A
    ,  
    Ferrie
    JE
    ,  
    Gimeno
    D
    ,  
    Marmot
    MG
    ,  
    Elovainio
    M
    .  
    et al.
    Long working hours and cognitive function: the Whitehall II Study.
    Am J Epidemiol
    2009
    169
    596
    605
     PubMed
  86. Yu
    F
    ,  
    Ryan
    LH
    ,  
    Schaie
    KW
    ,  
    Willis
    SL
    ,  
    Kolanowski
    A
    .  
    Factors associated with cognition in adults: the Seattle Longitudinal Study.
    Res Nurs Health
    2009
    32
    540
    50
     PubMed
  87. Wilson
    RS
    ,  
    Krueger
    KR
    ,  
    Arnold
    SE
    ,  
    Schneider
    JA
    ,  
    Kelly
    JF
    ,  
    Barnes
    LL
    .  
    et al.
    Loneliness and risk of Alzheimer disease.
    Arch Gen Psychiatry
    2007
    64
    234
    40
     PubMed
  88. Håkansson
    K
    ,  
    Rovio
    S
    ,  
    Helkala
    EL
    ,  
    Vilska
    AR
    ,  
    Winblad
    B
    ,  
    Soininen
    H
    .  
    et al.
    Association between mid-life marital status and cognitive function in later life: population based cohort study.
    BMJ
    2009
    339
    b2462
     PubMed
  89. Barnes
    LL
    ,  
    Mendes de Leon
    CF
    ,  
    Wilson
    RS
    ,  
    Bienias
    JL
    ,  
    Evans
    DA
    .  
    Social resources and cognitive decline in a population of older African Americans and whites.
    Neurology
    2004
    63
    2322
    6
     PubMed
  90. Holtzman
    RE
    ,  
    Rebok
    GW
    ,  
    Saczynski
    JS
    ,  
    Kouzis
    AC
    ,  
    Wilcox Doyle
    K
    ,  
    Eaton
    WW
    .  
    Social network characteristics and cognition in middle-aged and older adults.
    J Gerontol B Psychol Sci Soc Sci
    2004
    59
    P278
    84
     PubMed
  91. Green
    AF
    ,  
    Rebok
    G
    ,  
    Lyketsos
    CG
    .  
    Influence of social network characteristics on cognition and functional status with aging.
    Int J Geriatr Psychiatry
    2008
    23
    972
    8
     PubMed
  92. Seeman
    TE
    ,  
    Lusignolo
    TM
    ,  
    Albert
    M
    ,  
    Berkman
    L
    .  
    Social relationships, social support, and patterns of cognitive aging in healthy, high-functioning older adults: MacArthur studies of successful aging.
    Health Psychol
    2001
    20
    243
    55
     PubMed
  93. Aartsen
    MJ
    ,  
    Van Tilburg
    T
    ,  
    Smits
    CH
    ,  
    Comijs
    HC
    ,  
    Knipscheer
    KC
    .  
    Does widowhood affect memory performance of older persons?
    Psychol Med
    2005
    35
    217
    26
     PubMed
  94. van Gelder
    BM
    ,  
    Tijhuis
    M
    ,  
    Kalmijn
    S
    ,  
    Giampaoli
    S
    ,  
    Nissinen
    A
    ,  
    Kromhout
    D
    .  
    Marital status and living situation during a 5-year period are associated with a subsequent 10-year cognitive decline in older men: the FINE Study.
    J Gerontol B Psychol Sci Soc Sci
    2006
    61
    P213
    9
     PubMed
  95. Ho
    SC
    ,  
    Woo
    J
    ,  
    Sham
    A
    ,  
    Chan
    SG
    ,  
    Yu
    AL
    .  
    A 3-year follow-up study of social, lifestyle and health predictors of cognitive impairment in a Chinese older cohort.
    Int J Epidemiol
    2001
    30
    1389
    96
     PubMed
  96. Zunzunegui
    MV
    ,  
    Alvarado
    BE
    ,  
    Del Ser
    T
    ,  
    Otero
    A
    .  
    Social networks, social integration, and social engagement determine cognitive decline in community-dwelling Spanish older adults.
    J Gerontol B Psychol Sci Soc Sci
    2003
    58
    S93
    S100
     PubMed
  97. Muniz-Terrera
    G
    ,  
    Matthews
    F
    ,  
    Dening
    T
    ,  
    Huppert
    FA
    ,  
    Brayne
    C
    .  
    CC75C Group
    Education and trajectories of cognitive decline over 9 years in very old people: methods and risk analysis.
    Age Ageing
    2009
    38
    277
    82
     PubMed
  98. Bosma
    H
    ,  
    van Boxtel
    MP
    ,  
    Ponds
    RW
    ,  
    Jelicic
    M
    ,  
    Houx
    P
    ,  
    Metsemakers
    J
    .  
    et al.
    Engaged lifestyle and cognitive function in middle and old-aged, non-demented persons: a reciprocal association?
    Z Gerontol Geriatr
    2002
    35
    575
    81
     PubMed
  99. Niti
    M
    ,  
    Yap
    KB
    ,  
    Kua
    EH
    ,  
    Tan
    CH
    ,  
    Ng
    TP
    .  
    Physical, social and productive leisure activities, cognitive decline and interaction with APOE-epsilon 4 genotype in Chinese older adults.
    Int Psychogeriatr
    2008
    20
    237
    51
     PubMed
  100. Anstey
    KJ
    ,  
    Mack
    HA
    ,  
    Cherbuin
    N
    .  
    Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies.
    Am J Geriatr Psychiatry
    2009
    17
    542
    55
     PubMed
  101. Ganguli
    M
    ,  
    Vander Bilt
    J
    ,  
    Saxton
    JA
    ,  
    Shen
    C
    ,  
    Dodge
    HH
    .  
    Alcohol consumption and cognitive function in late life: a longitudinal community study.
    Neurology
    2005
    65
    1210
    7
     PubMed
  102. Dufouil
    C
    ,  
    Tzourio
    C
    ,  
    Brayne
    C
    ,  
    Berr
    C
    ,  
    Amouyel
    P
    ,  
    Alpérovitch
    A
    .  
    Influence of apolipoprotein E genotype on the risk of cognitive deterioration in moderate drinkers and smokers.
    Epidemiology
    2000
    11
    280
    4
     PubMed
  103. Wright
    CB
    ,  
    Elkind
    MS
    ,  
    Luo
    X
    ,  
    Paik
    MC
    ,  
    Sacco
    RL
    .  
    Reported alcohol consumption and cognitive decline: The northern Manhattan study.
    Neuroepidemiology
    2006
    27
    201
    7
     PubMed
  104. Stott
    DJ
    ,  
    Falconer
    A
    ,  
    Kerr
    GD
    ,  
    Murray
    HM
    ,  
    Trompet
    S
    ,  
    Westendorp
    RG
    .  
    et al.
    Does low to moderate alcohol intake protect against cognitive decline in older people?
    J Am Geriatr Soc
    2008
    56
    2217
    24
     PubMed
  105. Solfrizzi
    V
    ,  
    D'Introno
    A
    ,  
    Colacicco
    AM
    ,  
    Capurso
    C
    ,  
    Del Parigi
    A
    ,  
    Baldassarre
    G
    .  
    et al.
    Italian Longitudinal Study on Aging Working Group
    Alcohol consumption, mild cognitive impairment, and progression to dementia.
    Neurology
    2007
    68
    1790
    9
     PubMed
  106. Shadlen
    MF
    ,  
    Larson
    EB
    ,  
    Wang
    L
    ,  
    Phelan
    EA
    ,  
    McCormick
    WC
    ,  
    Jolley
    L
    .  
    et al.
    Education modifies the effect of apolipoprotein epsilon 4 on cognitive decline.
    Neurobiol Aging
    2005
    26
    17
    24
     PubMed
  107. Christensen
    H
    ,  
    Batterham
    PJ
    ,  
    Mackinnon
    AJ
    ,  
    Jorm
    AF
    ,  
    Mack
    HA
    ,  
    Mather
    KA
    .  
    et al.
    The association of APOE genotype and cognitive decline in interaction with risk factors in a 65-69 year old community sample.
    BMC Geriatr
    2008
    8
    14
     PubMed
  108. Wilson
    RS
    ,  
    Bienias
    JL
    ,  
    Berry-Kravis
    E
    ,  
    Evans
    DA
    ,  
    Bennett
    DA
    .  
    The apolipoprotein E epsilon 2 allele and decline in episodic memory.
    J Neurol Neurosurg Psychiatry
    2002
    73
    672
    7
     PubMed
  109. Bretsky
    P
    ,  
    Guralnik
    JM
    ,  
    Launer
    L
    ,  
    Albert
    M
    ,  
    Seeman
    TE
    .  
    MacArthur Studies of Successful Aging
    The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging.
    Neurology
    2003
    60
    1077
    81
     PubMed
  110. Blair
    CK
    ,  
    Folsom
    AR
    ,  
    Knopman
    DS
    ,  
    Bray
    MS
    ,  
    Mosley
    TH
    ,  
    Boerwinkle
    E
    .  
    Atherosclerosis Risk in Communities (ARIC) Study Investigators
    APOE genotype and cognitive decline in a middle-aged cohort.
    Neurology
    2005
    64
    268
    76
     PubMed
  111. Staehelin
    HB
    ,  
    Perrig-Chiello
    P
    ,  
    Mitrache
    C
    ,  
    Miserez
    AR
    ,  
    Perrig
    WJ
    .  
    Apolipoprotein E genotypes and cognitive functions in healthy elderly persons.
    Acta Neurol Scand
    1999
    100
    53
    60
     PubMed
  112. Yaffe
    K
    ,  
    Cauley
    J
    ,  
    Sands
    L
    ,  
    Browner
    W
    .  
    Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women.
    Arch Neurol
    1997
    54
    1110
    4
     PubMed
  113. Dik
    MG
    ,  
    Jonker
    C
    ,  
    Bouter
    LM
    ,  
    Geerlings
    MI
    ,  
    van Kamp
    GJ
    ,  
    Deeg
    DJ
    .  
    APOE-epsilon4 is associated with memory decline in cognitively impaired elderly.
    Neurology
    2000
    54
    1492
    7
     PubMed
  114. Haan
    MN
    ,  
    Shemanski
    L
    ,  
    Jagust
    WJ
    ,  
    Manolio
    TA
    ,  
    Kuller
    L
    .  
    The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons.
    JAMA
    1999
    282
    40
    6
     PubMed
  115. Lambert
    JC
    ,  
    Heath
    S
    ,  
    Even
    G
    ,  
    Campion
    D
    ,  
    Sleegers
    K
    ,  
    Hiltunen
    M
    .  
    et al.
    European Alzheimer's Disease Initiative Investigators
    Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease.
    Nat Genet
    2009
    41
    1094
    9
     PubMed
  116. Morris
    MC
    ,  
    Evans
    DA
    ,  
    Bienias
    JL
    ,  
    Scherr
    PA
    ,  
    Tangney
    CC
    ,  
    Hebert
    LE
    .  
    et al.
    Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline.
    J Neurol Neurosurg Psychiatry
    2004
    75
    1093
    9
     PubMed
  117. Morris
    MC
    ,  
    Evans
    DA
    ,  
    Bienias
    JL
    ,  
    Tangney
    CC
    ,  
    Hebert
    LE
    ,  
    Scherr
    PA
    .  
    et al.
    Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons.
    Arch Neurol
    2005
    62
    641
    5
     PubMed
  118. de Lau
    LM
    ,  
    Smith
    AD
    ,  
    Refsum
    H
    ,  
    Johnston
    C
    ,  
    Breteler
    MM
    .  
    Plasma vitamin B12 status and cerebral white-matter lesions.
    J Neurol Neurosurg Psychiatry
    2009
    80
    149
    57
     PubMed
  119. Maxwell
    CJ
    ,  
    Hicks
    MS
    ,  
    Hogan
    DB
    ,  
    Basran
    J
    ,  
    Ebly
    EM
    .  
    Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia.
    Dement Geriatr Cogn Disord
    2005
    20
    45
    51
     PubMed
  120. Morris
    MC
    ,  
    Evans
    DA
    ,  
    Tangney
    CC
    ,  
    Bienias
    JL
    ,  
    Wilson
    RS
    ,  
    Aggarwal
    NT
    .  
    et al.
    Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change.
    Am J Clin Nutr
    2005
    81
    508
    14
     PubMed
  121. Fotuhi
    M
    ,  
    Zandi
    PP
    ,  
    Hayden
    KM
    ,  
    Khachaturian
    AS
    ,  
    Szekely
    CA
    ,  
    Wengreen
    H
    .  
    et al.
    Better cognitive performance in elderly taking antioxidant vitamins E and C supplements in combination with nonsteroidal anti-inflammatory drugs: the Cache County Study.
    Alzheimers Dement
    2008
    4
    223
    7
     PubMed
  122. Morris
    MC
    ,  
    Evans
    DA
    ,  
    Bienias
    JL
    ,  
    Tangney
    CC
    ,  
    Wilson
    RS
    .  
    Vitamin E and cognitive decline in older persons.
    Arch Neurol
    2002
    59
    1125
    32
     PubMed
  123. Wengreen
    HJ
    ,  
    Munger
    RG
    ,  
    Corcoran
    CD
    ,  
    Zandi
    P
    ,  
    Hayden
    KM
    ,  
    Fotuhi
    M
    .  
    et al.
    Antioxidant intake and cognitive function of elderly men and women: the Cache County Study.
    J Nutr Health Aging
    2007
    11
    230
    7
     PubMed
  124. Kang
    JH
    ,  
    Grodstein
    F
    .  
    Plasma carotenoids and tocopherols and cognitive function: a prospective study.
    Neurobiol Aging
    2008
    29
    1394
    403
     PubMed
  125. Kalmijn
    S
    ,  
    Feskens
    EJ
    ,  
    Launer
    LJ
    ,  
    Kromhout
    D
    .  
    Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men.
    Am J Epidemiol
    1997
    145
    33
    41
     PubMed
  126. Fotuhi
    M
    ,  
    Mohassel
    P
    ,  
    Yaffe
    K
    .  
    Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association.
    Nat Clin Pract Neurol
    2009
    5
    140
    52
     PubMed
  127. Beydoun
    MA
    ,  
    Kaufman
    JS
    ,  
    Sloane
    PD
    ,  
    Heiss
    G
    ,  
    Ibrahim
    J
    .  
    n-3 Fatty acids, hypertension and risk of cognitive decline among older adults in the Atherosclerosis Risk in Communities (ARIC) study.
    Public Health Nutr
    2008
    11
    17
    29
     PubMed
  128. Dullemeijer
    C
    ,  
    Durga
    J
    ,  
    Brouwer
    IA
    ,  
    van de Rest
    O
    ,  
    Kok
    FJ
    ,  
    Brummer
    RJ
    .  
    et al.
    n 3 fatty acid proportions in plasma and cognitive performance in older adults.
    Am J Clin Nutr
    2007
    86
    1479
    85
     PubMed
  129. Arvanitakis
    Z
    ,  
    Schneider
    JA
    ,  
    Wilson
    RS
    ,  
    Bienias
    JL
    ,  
    Kelly
    JF
    ,  
    Evans
    DA
    .  
    et al.
    Statins, incident Alzheimer disease, change in cognitive function, and neuropathology.
    Neurology
    2008
    70
    1795
    802
     PubMed
  130. Agostini
    JV
    ,  
    Tinetti
    ME
    ,  
    Han
    L
    ,  
    McAvay
    G
    ,  
    Foody
    JM
    ,  
    Concato
    J
    .  
    Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults.
    J Am Geriatr Soc
    2007
    55
    420
    5
     PubMed
  131. Bernick
    C
    ,  
    Katz
    R
    ,  
    Smith
    NL
    ,  
    Rapp
    S
    ,  
    Bhadelia
    R
    ,  
    Carlson
    M
    .  
    et al.
    Cardiovascular Health Study Collaborative Research Group
    Statins and cognitive function in the elderly: the Cardiovascular Health Study.
    Neurology
    2005
    65
    1388
    94
     PubMed
  132. Szwast
    SJ
    ,  
    Hendrie
    HC
    ,  
    Lane
    KA
    ,  
    Gao
    S
    ,  
    Taylor
    SE
    ,  
    Unverzagt
    F
    .  
    et al.
    Association of statin use with cognitive decline in elderly African Americans.
    Neurology
    2007
    69
    1873
    80
     PubMed
  133. van de Rest
    O
    ,  
    Geleijnse
    JM
    ,  
    Kok
    FJ
    ,  
    van Staveren
    WA
    ,  
    Dullemeijer
    C
    ,  
    Olderikkert
    MG
    .  
    et al.
    Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial.
    Neurology
    2008
    71
    430
    8
     PubMed
  134. McGuinness
    B
    ,  
    Craig
    D
    ,  
    Bullock
    R
    ,  
    Passmore
    P
    .  
    Statins for the prevention of dementia.
    Cochrane Database Syst Rev
    2009
    CD003160
     PubMed
  135. McGuinness
    B
    ,  
    Todd
    S
    ,  
    Passmore
    P
    ,  
    Bullock
    R
    .  
    Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia.
    Cochrane Database Syst Rev
    2009
    CD004034
     PubMed
  136. Lithell
    H
    ,  
    Hansson
    L
    ,  
    Skoog
    I
    ,  
    Elmfeldt
    D
    ,  
    Hofman
    A
    ,  
    Olofsson
    B
    .  
    et al.
    SCOPE Study Group
    The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
    J Hypertens
    2003
    21
    875
    86
     PubMed
  137. Hayden
    KM
    ,  
    Zandi
    PP
    ,  
    Khachaturian
    AS
    ,  
    Szekely
    CA
    ,  
    Fotuhi
    M
    ,  
    Norton
    MC
    .  
    et al.
    Cache County Investigators
    Does NSAID use modify cognitive trajectories in the elderly? The Cache County study.
    Neurology
    2007
    69
    275
    82
     PubMed
  138. Jonker
    C
    ,  
    Comijs
    HC
    ,  
    Smit
    JH
    .  
    Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study.
    Neurobiol Aging
    2003
    24
    583
    8
     PubMed
  139. Grodstein
    F
    ,  
    Skarupski
    KA
    ,  
    Bienias
    JL
    ,  
    Wilson
    RS
    ,  
    Bennett
    DA
    ,  
    Evans
    DA
    .  
    Anti-inflammatory agents and cognitive decline in a bi-racial population.
    Neuroepidemiology
    2008
    30
    45
    50
     PubMed
  140. Hee Kang
    J
    ,  
    Grodstein
    F
    .  
    Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women.
    Neurology
    2003
    60
    1591
    7
     PubMed
  141. LeBlanc
    ES
    ,  
    Janowsky
    J
    ,  
    Chan
    BK
    ,  
    Nelson
    HD
    .  
    Hormone replacement therapy and cognition: systematic review and meta-analysis.
    JAMA
    2001
    285
    1489
    99
     PubMed
  142. Ryan
    J
    ,  
    Carrière
    I
    ,  
    Scali
    J
    ,  
    Ritchie
    K
    ,  
    Ancelin
    ML
    .  
    Life-time estrogen exposure and cognitive functioning in later life.
    Psychoneuroendocrinology
    2009
    34
    287
    98
     PubMed
  143. Laurin
    D
    ,  
    Verreault
    R
    ,  
    Lindsay
    J
    ,  
    MacPherson
    K
    ,  
    Rockwood
    K
    .  
    Physical activity and risk of cognitive impairment and dementia in elderly persons.
    Arch Neurol
    2001
    58
    498
    504
     PubMed
  144. Verghese
    J
    ,  
    LeValley
    A
    ,  
    Derby
    C
    ,  
    Kuslansky
    G
    ,  
    Katz
    M
    ,  
    Hall
    C
    .  
    et al.
    Leisure activities and the risk of amnestic mild cognitive impairment in the elderly.
    Neurology
    2006
    66
    821
    7
     PubMed
  145. Lytle
    ME
    ,  
    Vander Bilt
    J
    ,  
    Pandav
    RS
    ,  
    Dodge
    HH
    ,  
    Ganguli
    M
    .  
    Exercise level and cognitive decline: the MoVIES project.
    Alzheimer Dis Assoc Disord
    2004
    18
    57
    64
     PubMed
  146. Schuit
    AJ
    ,  
    Feskens
    EJ
    ,  
    Launer
    LJ
    ,  
    Kromhout
    D
    .  
    Physical activity and cognitive decline, the role of the apolipoprotein e4 allele.
    Med Sci Sports Exerc
    2001
    33
    772
    7
     PubMed
  147. Yaffe
    K
    ,  
    Barnes
    D
    ,  
    Nevitt
    M
    ,  
    Lui
    LY
    ,  
    Covinsky
    K
    .  
    A prospective study of physical activity and cognitive decline in elderly women: women who walk.
    Arch Intern Med
    2001
    161
    1703
    8
     PubMed
  148. Wilson
    RS
    ,  
    Bennett
    DA
    ,  
    Bienias
    JL
    ,  
    Mendes de Leon
    CF
    ,  
    Morris
    MC
    ,  
    Evans
    DA
    .  
    Cognitive activity and cognitive decline in a biracial community population.
    Neurology
    2003
    61
    812
    6
     PubMed
  149. Kang
    JH
    ,  
    Cook
    N
    ,  
    Manson
    J
    ,  
    Buring
    JE
    ,  
    Albert
    CM
    ,  
    Grodstein
    F
    .  
    A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease.
    Am J Clin Nutr
    2008
    88
    1602
    10
     PubMed
  150. McMahon
    JA
    ,  
    Green
    TJ
    ,  
    Skeaff
    CM
    ,  
    Knight
    RG
    ,  
    Mann
    JI
    ,  
    Williams
    SM
    .  
    A controlled trial of homocysteine lowering and cognitive performance.
    N Engl J Med
    2006
    354
    2764
    72
     PubMed
  151. McNeill
    G
    ,  
    Avenell
    A
    ,  
    Campbell
    MK
    ,  
    Cook
    JA
    ,  
    Hannaford
    PC
    ,  
    Kilonzo
    MM
    .  
    et al.
    Effect of multivitamin and multimineral supplementation on cognitive function in men and women aged 65 years and over: a randomised controlled trial.
    Nutr J
    2007
    6
    10
     PubMed
  152. Kang
    JH
    ,  
    Cook
    N
    ,  
    Manson
    J
    ,  
    Buring
    JE
    ,  
    Grodstein
    F
    .  
    A randomized trial of vitamin E supplementation and cognitive function in women.
    Arch Intern Med
    2006
    166
    2462
    8
     PubMed
  153. Smith
    A
    ,  
    Clark
    R
    ,  
    Nutt
    D
    ,  
    Haller
    J
    ,  
    Hayward
    S
    ,  
    Perry
    K
    .  
    et al.
    Anti-oxidant vitamins and mental performance of the elderly.
    Hum Psychopharmacol Clin Exp
    1999
    14
    459
    71
  154. Kang
    JH
    ,  
    Cook
    NR
    ,  
    Manson
    JE
    ,  
    Buring
    JE
    ,  
    Albert
    CM
    ,  
    Grodstein
    F
    .  
    Vitamin E, vitamin C, β carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women's Antioxidant and Cardiovascular Study.
    Circulation
    2009
    119
    2772
    80
     PubMed
  155. Dodge
    HH
    ,  
    Zitzelberger
    T
    ,  
    Oken
    BS
    ,  
    Howieson
    D
    ,  
    Kaye
    J
    .  
    A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline.
    Neurology
    2008
    70
    1809
    17
     PubMed
  156. Applegate
    WB
    ,  
    Pressel
    S
    ,  
    Wittes
    J
    ,  
    Luhr
    J
    ,  
    Shekelle
    RB
    ,  
    Camel
    GH
    .  
    et al.
    Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program.
    Arch Intern Med
    1994
    154
    2154
    60
     PubMed
  157. Saxby
    BK
    ,  
    Harrington
    F
    ,  
    Wesnes
    KA
    ,  
    McKeith
    IG
    ,  
    Ford
    GA
    .  
    Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial.
    Neurology
    2008
    70
    1858
    66
     PubMed
  158. Skoog
    I
    ,  
    Lithell
    H
    ,  
    Hansson
    L
    ,  
    Elmfeldt
    D
    ,  
    Hofman
    A
    ,  
    Olofsson
    B
    .  
    et al.
    SCOPE Study Group
    Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE).
    Am J Hypertens
    2005
    18
    1052
    9
     PubMed
  159. Prince
    MJ
    ,  
    Bird
    AS
    ,  
    Blizard
    RA
    ,  
    Mann
    AH
    .  
    Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults.
    BMJ
    1996
    312
    801
    5
     PubMed
  160. Tzourio
    C
    ,  
    Anderson
    C
    ,  
    Chapman
    N
    ,  
    Woodward
    M
    ,  
    Neal
    B
    ,  
    MacMahon
    S
    .  
    et al.
    PROGRESS Collaborative Group
    Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease.
    Arch Intern Med
    2003
    163
    1069
    75
     PubMed
  161. Kang
    JH
    ,  
    Cook
    N
    ,  
    Manson
    J
    ,  
    Buring
    JE
    ,  
    Grodstein
    F
    .  
    Low dose aspirin and cognitive function in the women's health study cognitive cohort.
    BMJ
    2007
    334
    987
     PubMed
  162. Price
    JF
    ,  
    Stewart
    MC
    ,  
    Deary
    IJ
    ,  
    Murray
    GD
    ,  
    Sandercock
    P
    ,  
    Butcher
    I
    .  
    et al.
    AAA Trialists
    Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial.
    BMJ
    2008
    337
    a1198
     PubMed
  163. Martin
    BK
    ,  
    Szekely
    C
    ,  
    Brandt
    J
    ,  
    Piantadosi
    S
    ,  
    Breitner
    JC
    ,  
    Craft
    S
    .  
    et al.
    ADAPT Research Group
    Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
    Arch Neurol
    2008
    65
    896
    905
     PubMed
  164. Grimley Evans
    J
    ,  
    Malouf
    R
    ,  
    Huppert
    F
    ,  
    van Niekerk
    JK
    .  
    Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people.
    Cochrane Database Syst Rev
    2006
    CD006221
     PubMed
  165. Lethaby
    A
    ,  
    Hogervorst
    E
    ,  
    Richards
    M
    ,  
    Yesufu
    A
    ,  
    Yaffe
    K
    .  
    Hormone replacement therapy for cognitive function in postmenopausal women.
    Cochrane Database Syst Rev
    2008
    CD003122
     PubMed
  166. Nickelsen
    T
    ,  
    Lufkin
    EG
    ,  
    Riggs
    BL
    ,  
    Cox
    DA
    ,  
    Crook
    TH
    .  
    Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women.
    Psychoneuroendocrinology
    1999
    24
    115
    28
     PubMed
  167. Tierney
    MC
    ,  
    Oh
    P
    ,  
    Moineddin
    R
    ,  
    Greenblatt
    EM
    ,  
    Snow
    WG
    ,  
    Fisher
    RH
    .  
    et al.
    A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women.
    Psychoneuroendocrinology
    2009
    34
    1065
    74
     PubMed
  168. Kritz-Silverstein
    D
    ,  
    von Mühlen
    D
    ,  
    Laughlin
    GA
    ,  
    Bettencourt
    R
    .  
    Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial.
    J Am Geriatr Soc
    2008
    56
    1292
    8
     PubMed
  169. Petersen
    RC
    ,  
    Thomas
    RG
    ,  
    Grundman
    M
    ,  
    Bennett
    D
    ,  
    Doody
    R
    ,  
    Ferris
    S
    .  
    et al.
    Alzheimer's Disease Cooperative Study Group
    Vitamin E and donepezil for the treatment of mild cognitive impairment.
    N Engl J Med
    2005
    352
    2379
    88
     PubMed
  170. Raschetti
    R
    ,  
    Albanese
    E
    ,  
    Vanacore
    N
    ,  
    Maggini
    M
    .  
    Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials.
    PLoS Med
    2007
    4
    338
     PubMed
  171. Doody
    RS
    ,  
    Ferris
    SH
    ,  
    Salloway
    S
    ,  
    Sun
    Y
    ,  
    Goldman
    R
    ,  
    Watkins
    WE
    .  
    et al.
    Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Neurology
    2009
    72
    1555
    61
     PubMed
  172. Yesavage
    JA
    ,  
    Friedman
    L
    ,  
    Ashford
    JW
    ,  
    Kraemer
    HC
    ,  
    Mumenthaler
    MS
    ,  
    Noda
    A
    .  
    et al.
    Acetylcholinesterase inhibitor in combination with cognitive training in older adults.
    J Gerontol B Psychol Sci Soc Sci
    2008
    63
    P288
    94
     PubMed
  173. Lautenschlager
    NT
    ,  
    Cox
    KL
    ,  
    Flicker
    L
    ,  
    Foster
    JK
    ,  
    van Bockxmeer
    FM
    ,  
    Xiao
    J
    .  
    et al.
    Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial.
    JAMA
    2008
    300
    1027
    37
     PubMed
  174. Willis
    SL
    ,  
    Tennstedt
    SL
    ,  
    Marsiske
    M
    ,  
    Ball
    K
    ,  
    Elias
    J
    ,  
    Koepke
    KM
    .  
    et al.
    ACTIVE Study Group
    Long-term effects of cognitive training on everyday functional outcomes in older adults.
    JAMA
    2006
    296
    2805
    14
     PubMed
  175. Anstey
    KJ
    ,  
    von Sanden
    C
    ,  
    Salim
    A
    ,  
    O'Kearney
    R
    .  
    Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies.
    Am J Epidemiol
    2007
    166
    367
    78
     PubMed
  176. Ball
    K
    ,  
    Berch
    DB
    ,  
    Helmers
    KF
    ,  
    Jobe
    JB
    ,  
    Leveck
    MD
    ,  
    Marsiske
    M
    .  
    et al.
    Advanced Cognitive Training for Independent and Vital Elderly Study Group
    Effects of cognitive training interventions with older adults: a randomized controlled trial.
    JAMA
    2002
    288
    2271
    81
     PubMed
  177. Jüni
    P
    ,  
    Witschi
    A
    ,  
    Bloch
    R
    ,  
    Egger
    M
    .  
    The hazards of scoring the quality of clinical trials for meta-analysis.
    JAMA
    1999
    282
    1054
    60
     PubMed
  178. Egger
    M
    ,  
    Schneider
    M
    ,  
    Davey Smith
    G
    .  
    Spurious precision? Meta-analysis of observational studies.
    BMJ
    1998
    316
    140
    4
     PubMed

Appendix

This appendix describes further details of the methods we used for this systematic review. We addressed 6 questions in the original review:
Key question 1: What factors are associated with the reduction of risk of Alzheimer disease?
Key question 2: What factors are associated with the reduction of risk of cognitive decline in older adults?
Key question 3: What are the therapeutic and adverse effects of interventions to delay the onset of Alzheimer disease? Are there differences in outcomes among identifiable subgroups?
Key question 4: What are the therapeutic and adverse effects of interventions to improve or maintain cognitive ability or function? Are there different outcomes in identifiable subgroups?
Key question 5: What are the relationships between the factors that affect Alzheimer disease and the factors that affect cognitive decline?
Key question 6: If recommendations for interventions cannot be made currently, what studies need to be done to provide the quality and strength of evidence necessary to make such recommendations to individuals?
This systematic review focuses on key questions 2 and 4.
For all questions, we were interested in adults 50 years or older who were drawn from general populations. For key questions 1 and 2, we focused on factors that are not amenable to randomization (such as hypertension) and limited our review to observational studies. For key questions 3 and 4, we prioritized RCTs, but because the evidence was often sparse or limited to selected samples, we supplemented trial data with evidence from observational studies when necessary. For key question 5, we were interested in the consistency of findings for each exposure or intervention on risk for Alzheimer disease and cognitive decline.
Appendix Table 1 lists the exposures and interventions that we evaluated.

Appendix Table 1.

Exposures and Interventions

Appendix Table 1.

Analytic Framework

Our analytic framework (Appendix Figure) describes the progression from normal cognition, to the initiation of subclinical pathophysiologic processes, to cognitive decline that is beyond what is expected for normal aging, and finally to Alzheimer disease. Although primary prevention may be possible before the initiation of pathophysiologic processes that lead to cognitive decline, no well-validated methods exist to measure these processes in the absence of cognitive decline. Therefore, we did not consider effects of the candidate factors on changes in pathophysiologic processes. The Appendix Figure shows the potential for treatment interventions to affect cognitive decline and the risk for Alzheimer disease.
Appendix Figure.
Analytic framework.

CI = cognitive impairment; KQ = key question.

Literature Review Methods

Inclusion or Exclusion Criteria
After discussion with the technical expert panel, we generated article inclusion and exclusion criteria for the key questions (Appendix Table 2). Because of the many factors and interventions to review, we searched initially for good-quality systematic reviews. We included primary literature to update eligible reviews or when good-quality reviews were unavailable. We limited the primary literature to English-language comparative studies that enrolled adults 50 years or older who were drawn from general populations in economically developed countries. We defined general populations as those drawn primarily from noninstitutionalized community settings or general medical populations. With 3 exceptions, we limited observational studies to longitudinal designs in which the risk factor or intervention was measured before the outcome. We made exceptions for traumatic brain injury and toxic environmental exposures, because of the difficulty of studying these factors longitudinally, and for sleep apnea, because of the absence of cohort studies. Because Alzheimer disease is a relatively uncommon event, we required a sample size greater than 300 to focus on studies with higher statistical power. Because of the long subclinical prodromal phase of Alzheimer disease, we required at least 2 years between exposure and outcomes assessments in Alzheimer disease studies. To provide sufficient time for meaningful change to occur, we required at least 1 year for studies of cognitive decline.

Appendix Table 2.

Inclusion and Exclusion Criteria

Appendix Table 2.
Literature Search Strategies
On the basis of our inclusion and exclusion criteria, we generated a list of Medical Subject Heading (MeSH) search terms, supplemented by keyword searches, which we used to search MEDLINE. We developed search terms and strategies in consultation with a medical librarian. Our original report (7) details the exact search strategies we used. In addition to MEDLINE, we searched the Cochrane Database of Systematic Reviews to identify relevant systematic reviews. For topics with a recent good-quality systematic review, we updated the search by identifying relevant primary literature published from 1 year before the search end date through 27 October 2009. (The 1-year overlap is necessary because of delays between publication in journals and availability for searching in MEDLINE.) We included relevant older literature that was missed or excluded in previous reviews if it met our eligibility criteria.
When we did not identify a relevant good-quality review, we searched the primary literature to include studies from 1984 through 27 October 2009. We supplemented our electronic searching by examining the bibliographies of reviews and primary studies. Because of the large volume of literature and the availability of specialized registries for genetic studies, we developed a separate search strategy for this literature. We examined the HuGEpedia and AlzGene databases to identify relevant systematic reviews for genes identified as being of special interest, in consultation with the technical expert panel.
Using the prespecified inclusion and exclusion criteria, 2 reviewers independently examined titles and abstracts for potential relevance to the key questions. Articles included by either reviewer underwent full-text screening. At the full-text screening stage, 2 independent reviewers read each article to determine whether it met eligibility criteria. We resolved disagreements by consensus. At the full-text review stage, simple agreement was 84% and median chance corrected agreement had a κ value of 0.63 (range, 0.40 to 1.0). We included articles that met our eligibility criteria for data abstraction.

Data Abstraction and Data Management

One reviewer abstracted data from published reports into evidence tables and another overread them. The data elements we abstracted included descriptors to assess applicability, quality elements, intervention and exposure details, and outcomes. We resolved disagreements by consensus or by obtaining a third reviewer's opinion when consensus could not be reached. The final evidence tables are intended to provide sufficient information so that readers can understand the study and determine its quality and are available as part of the original report (7).

Assessment of Methodological Quality

We developed separate criteria for assessing the methodological quality of included systematic reviews, RCTs, and observational studies. In brief, for systematic reviews, we assessed the comprehensiveness of the search strategy, the description and appropriateness of inclusion criteria, whether primary studies were assessed for quality and the adequacy of the quality measure, the reproducibility of the methods to assess studies, whether the results of relevant studies were combined appropriately, whether heterogeneity and publication bias were assessed, and whether the conclusions were supported by the data presented.
For RCTs, we used the key criteria described in the AHRQ methods manual for comparative effectiveness reviews (4), adapted to this specific topic. These criteria are adequacy of randomization and allocation concealment, comparability of groups at baseline, adequacy of blinding, completeness of follow-up and differential loss to follow-up, appropriate addressing of incomplete data, validity of outcome measures, and degree of conflict of interest.
To assess individual observational studies, we adapted a basic set of quality criteria used in previous AHRQ evidence reports (5, 6). These criteria concern the methods used to select the cohort, the adequacy of the sample size, the methods used to ascertain exposure status and outcomes, the adequacy and completeness of follow-up, and the appropriateness of the analytic methods used. Abstractors assigned a rating of “yes,” “partially,” “no,” or “can't tell” to each item and provided a brief rationale for their decisions. We did not attempt to assign a summary quality score (such as “A, B, C” or “good, fair, poor”) to individual RCTs or observational studies, because no evidence indicates that the use of any particular quality scoring system has a substantial effect on the results of systematic reviews (177). In addition, our experience has been that it is more helpful to identify consistent and specific quality issues that affect most of the included studies (such as those that concern sample size, analytic methods, or ascertainment bias) to guide future research, rather than relying on a global quality score.
We used principles from the GRADE working group to summarize the quality of evidence for each factor as low, moderate, or high. The GRADE approach considers the body of evidence for each outcome and assigns an initial rating of low quality to observational studies and high quality to RCTs. These initial ratings may be modified by detailed study design, consistency, strength of association, dose–response effect, directness, precision, and whether all plausible confounding would reduce a demonstrated effect. A high rating reflects high confidence that the evidence reflects the true effect and that further research is very unlikely to change our confidence in the estimate of effect. A moderate rating reflects moderate confidence that the evidence reflects the true effect but a recognition that further research may change both our confidence in the estimate of effect and the estimate. A low rating reflects low confidence that the evidence reflects the true effect and indicates that further research is likely to change both our confidence in the estimate of effect and the estimate. A rating of “insufficient evidence” means that evidence either is unavailable or does not permit estimation of an effect. At least 2 reviewers judged the strength of evidence; we reached our final ratings by consensus.

Data Synthesis

When we identified good-quality systematic reviews, we summarized their findings in narrative form. We descriptively summarized any new studies identified since the systematic review was published in a table that included the study sample, exposure classification, duration of follow-up, adjustment for confounding, and primary outcomes. We evaluated whether the new evidence was likely to change estimates from the previous review by considering the precision and stability of estimates from the original review, the number and size of the new studies relative to those in the original review, the quality of the new studies, and the consistency in estimates and conclusions between the new evidence and the original review. After considering these issues, we updated previous meta-analyses when substantial new evidence was available and a new summary estimate was likely to lead to different conclusions. We performed primary meta-analysis when the studies were conceptually homogeneous and the needed data were available for the summary estimate. Because meta-analysis of observational studies may give spurious precision (178), we applied meta-analysis to observational data only when studies were of high quality and conceptually homogeneous (for example, containing similar participants, exposure, or outcomes).
Synthesizing studies that evaluated cognitive decline was particularly challenging. Cognitive decline can be classified categorically by meeting proposed criteria, such as those for MCI, or by exceeding a threshold on a global cognitive measure, such as the MMSE. We prioritized these categorical outcomes because they are often more clinically meaningful. Cognitive decline may also be examined by using continuous measures of global, isolated, domain-specific measures (such as memory or processing speed) or by composites of multiple measures for a domain. Many of these measures have not been demonstrated to be responsive to change, and any changes observed may be of uncertain clinical significance. Because of the heterogeneity of the continuous measures reported and the large scope of our review, we evaluated the relevance of studies that reported continuous measures for each exposure. When an adequate number of studies that used categorical outcomes addressed the question and when the results were similar from the categorical and continuous outcome studies, we did not provide detailed summaries of the studies that reported continuous outcomes.
Figure.
Literature search and selection.

RCTs = randomized, controlled trials.

Appendix Figure.
Analytic framework.

CI = cognitive impairment; KQ = key question.

Table 1.

Evidence of Association With Cognitive Decline for Factors With Observational Data Only

Table 1.

Table 2.

Evidence of Association With Cognitive Decline for Factors With Both Observational and RCT Data

Table 2.

Table 3.

Summary of Findings on Potential Risk Factors and Interventions for Cognitive Decline

Table 3.

Appendix Table 1.

Exposures and Interventions

Appendix Table 1.

Appendix Table 2.

Inclusion and Exclusion Criteria

Appendix Table 2.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Plassman BL, Williams JW, Burke JR, et al. Systematic Review: Factors Associated With Risk for and Possible Prevention of Cognitive Decline in Later Life. Ann Intern Med. 2010;153:182–193. doi: https://doi.org/10.7326/0003-4819-153-3-201008030-00258

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2010;153(3):182-193.

DOI: 10.7326/0003-4819-153-3-201008030-00258

316 Citations

See Also

National Institutes of Health State-of-the-Science Conference Statement: Preventing Alzheimer Disease and Cognitive Decline
View MoreView Less
CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×